Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Ibuprofen. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 5/20 | 0.66 |
| ▸ | PTGS2 known ✓ | P35354 | 5/20 | 0.66 |
| ▸ | THRB | P10828 | 1/20 | 0.73 |
| ▸ | CXCR1 | P25024 | 3/20 | 0.66 |
| ▸ | CXCR2 | P25025 | 3/20 | 0.66 |
| ▸ | LMNA | P02545 | 2/20 | 0.66 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.66 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.66 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.66 |
| ▸ | ALB | P02768 | 1/20 | 0.66 |
| ▸ | ESR1 | P03372 | 1/20 | 0.66 |
| ▸ | RARB | P10826 | 1/20 | 0.66 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.66 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.66 |
| ▸ | HTR2A | P28223 | 1/20 | 0.66 |
| ▸ | NR1I3 | Q14994 | 1/20 | 0.66 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.66 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.66 |
| ▸ | TSHR | P16473 | 1/20 | 0.66 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dexibuprofen SCHEMBL8733957 | 1.00 | THRB (0.73) | THRBPTGS1PTGS2CXCR1CXCR2 | |
| Ibuprofen SCHEMBL44617 | 1.00 | THRB (0.73) | THRBPTGS1PTGS2CXCR1CXCR2 | |
| (R)-Ibuprophen SCHEMBL29696062 | 1.00 | THRB (0.73) | THRBPTGS1PTGS2CXCR1CXCR2 | |
| (R)-Ibuprophen SCHEMBL8579043 | 1.00 | THRB (0.73) | THRBPTGS1PTGS2CXCR1CXCR2 | |
| Dexibuprofen SCHEMBL875767 | 1.00 | THRB (0.73) | THRBPTGS1PTGS2CXCR1CXCR2 | |
| Ibuprofen SCHEMBL8902943 | 0.99 | THRB (0.72) | THRBPTGS1PTGS2CXCR1CXCR2 | |
| Ibuprofen SCHEMBL8902948 | 0.99 | THRB (0.72) | THRBPTGS1PTGS2CXCR1CXCR2 | |
| Dexibuprofen SCHEMBL379398 | 0.99 | THRB (0.72) | THRBPTGS1PTGS2CXCR1CXCR2 | |
| Lysine SCHEMBL11276603 | 0.92 | THRB (0.71) | THRBPTGS1PTGS2CXCR1CXCR2 | |
| Ibuprofen SCHEMBL20775003 | 0.86 | PTGS1 (0.64) | THRBPTGS1PTGS2CXCR1CXCR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1126 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026104580-A1 | PHARMACEUTICAL COMPOSITIONS USING NON-ANIMAL ORIGIN MATRIX FORMERS AND METHODS OF MAKING THEREOF | CATALENT U.K. SWINDON ZYDIS LIMITED (GB) | 2026-05-21 | — | — | WO | claimed |
| US-20260131006-A1 | PHARMACEUTICAL COMPOSITIONS USING NON-ANIMAL ORIGIN MATRIX FORMERS AND METHODS OF MAKING THEREOF | CATALENT U.K. SWINDON ZYDIS LIMITED (GB) | 2026-05-14 | — | — | US | claimed |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | SIO2 MEDICAL PRODUCTS LLC (US) | 2026-03-19 | — | — | US | claimed |
| US-12514833-B2 | Combination of ibuprofen and tramadol for relieving pain | FARMALÍDER, S.A. (ES) | 2026-01-06 | — | — | US | claimed |
| EP-4482466-B1 | COMBINED THERAPEUTIC AGENT | MARIA CLEMENTINE MARTIN KLOSTERFRAU VERTRIEBSGES MBH (DE) | 2025-11-05 | — | — | EP | claimed |
| US-20250242092-A1 | SiOx BARRIER FOR PHARMACEUTICAL PACKAGE AND COATING PROCESS | SIO2 MEDICAL PRODUCTS INC (US) | 2025-07-31 | — | — | US | claimed |
| US-12257371-B2 | SiOx barrier for pharmaceutical package and coating process | SIO2 MEDICAL PRODUCTS, LLC (US) | 2025-03-25 | — | — | US | claimed |
| WO-2025046047-A1 | PHARMACEUTICAL COMPOSITION OF COMBINATION OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) AND DECONGESTANT IN THE FORM OF A POWDER OR GRANULES FOR PREPARING A HOT DRINK | GRINDEKS, A JOINT STOCK COMPANY (LV) | 2025-03-06 | — | — | WO | claimed |
| EP-4516290-A1 | PHARMACEUTICAL COMPOSITION OF COMBINATION OF A NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS) AND DECONGESTANT IN THE FORM OF A POWDER OR GRANULES FOR PREPARING A HOT DRINK | Grindeks, A Joint Stock Company (LV) | 2025-03-05 | — | — | EP | claimed |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | HOTH THERAPEUTICS, INC. | 2025-01-30 | — | — | US | claimed |
| EP-0440462-B1 | Sustained release with high and low viscosity HPMC | MERCK & CO INC (US) | 1994-12-28 | — | — | EP | claimed |
| EP-0253083-B1 | Topical vaginal use of lysine p-isobutylphenylpropionate in antiinflammatory treatment | LISAPHARMA SPA (IT) | 1994-08-31 | — | — | EP | claimed |
| WO-1994016703-A1 | CICLOBENZAPRINE-CAFFEINE COMBINATION AS A MUSCLE RELAXANT | MERCK & CO., INC. (US) | 1994-08-04 | — | — | WO | claimed |
| EP-0505180-A1 | High-content ibuprofen lysinate pharmaceutical formulation | MERCK & CO. INC. (US) | 1992-09-23 | — | — | EP | claimed |
| EP-0491897-A1 | LIQUID ORAL PHARMACEUTICAL COMPOSITIONS HAVING ANTI-INFLAMMATORY ACTIVITY | L.C. PHARCHEM Ltd. (CY) | 1992-07-01 | — | — | EP | claimed |
| WO-1992000725-A1 | LIQUID ORAL PHARMACEUTICAL COMPOSITIONS HAVING ANTI-INFLAMMATORY ACTIVITY | FARCON AG (LI) | 1992-01-23 | — | — | WO | claimed |
| EP-0440462-A1 | Sustained release with high and low viscosity HPMC | MERCK & CO. INC. (US) | 1991-08-07 | — | — | EP | claimed |
| US-5009895-A | Hydroxypropyl methyl cellulose shaped and compressed into a solid dosage form having a zero order release profile upon administration | MERCK & CO., INC. (US) | 1991-04-23 | — | — | US | claimed |
| US-4755533-A | Topical vaginal use of lysine p-isobutylphenylpropionate in anti-inflammatory treatment | LABORATORIO ITALIANO BIOCHIMICO FARMACEUTICO LISAPHARMA SPA (IT) | 1988-07-05 | — | — | US | claimed |
| EP-0253083-A2 | Topical vaginal use of lysine p-isobutylphenylpropionate in antiinflammatory treatment | LABORATORIO ITALIANO BIOCHIMICO FARMACEUTICO LISAPHARMA S.P.A. (IT) | 1988-01-20 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260131006-A1 | PHARMACEUTICAL COMPOSITIONS USING NON-ANIMAL ORIGIN MATRIX FORMERS AND METHODS OF MAKING THEREOF | GYS1, OGT, SUGT1 | PTGS1 908/4885PTGS2 1245/4885THRB 4877/4885 |
| US-20250032503-A1 | USE OF APREPITANT FOR TREATING ALZHEIMER'S DISEASE | TACR1, ACHE, TACR2 | PTGS1 437/4885PTGS2 689/4885THRB 2267/4885 |
| US-20260076872-A1 | POLYMER VIALS WITH SUBSTANTIALLY FLAT BOTTOMS AND INJECTION STRETCH BLOW MOLDING METHODS FOR MAKING THE SAME | MEN1, MYO1G, IL2 | PTGS1 2336/4885PTGS2 3239/4885THRB 582/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.